抗肥満治療薬市場：治療タイプ、薬剤タイプ、投与経路、剤形、エンドユーザー、流通チャネル別-2025-2030年世界予測

抗肥満治療薬市場は、2024年には107億9,000万米ドルとなり、2025年にはCAGR 8.59%で116億9,000万米ドルに成長し、2030年には177億米ドルに達すると予測されています。

抗肥満治療薬セクターは著しい進化を遂げ、革新的治療と包括的ヘルスケア戦略に新たな重点を置いています。最近の進歩により、世界的に数百万人が罹患しているこの疾患に対する効果的な治療オプションや処置の重要性が高まっています。肥満が公衆衛生の主要な関心事であり続ける中、治療的介入のための研究開発への多額の投資がダイナミックな市場環境を牽引しています。

本分析では、臨床的イノベーション、患者中心のアプローチ、市場動向を織り交ぜながら、治療情勢の全体像を展望します。薬剤製剤や外科的介入における最近の改良は、抗肥満ソリューションの範囲が広がっていることを反映しています。政府と民間利害関係者がウェルネスと予防医療を優先させる中、市場はターゲットを絞った個別化レジメンへと移行しています。ヘルスケア専門家、投資家、政策立案者を含む利害関係者は、現在の実践と将来の機会の両方について明確な見解を提供するデータ主導型の洞察をますます求めるようになっています。以下のセクションでは、治療領域における変革的なシフト、詳細なセグメンテーションに関する洞察、地域別の市場ダイナミクス、この重要な領域で事業を展開する主要企業の戦略的展望を掘り下げて解説します。

本レポートは、患者ケアを再定義しつつある収束しつつある動向を受け入れるためのガイドであり、呼びかけでもあります。科学的進歩への継続的な取り組みが、現実的な規制の調整と消費者の要望と相まって、抗肥満治療市場を大きく混乱させる舞台となっています。

抗肥満治療薬市場の変革

近年、抗肥満治療薬を取り巻く環境は大きく変化しています。技術革新、より深い臨床的洞察、進化する患者ニーズの融合が、治療アプローチの根本的な変革に拍車をかけています。医薬品開発と精密医療の進歩は、より効果的でオーダーメイドの治療法への道を開いた。同市場では、従来の薬物療法と革新的な外科的介入が統合され、複雑な患者プロファイルに対応する統合的な治療計画が可能になりつつあります。

規制の枠組みの変化と医学研究への投資の増加が、こうした変化をさらに加速させています。新たな臨床試験、長期的な有効性に関する確かなデータ、製薬企業間の戦略的パートナーシップは、治療の新たな道筋を切り開く上で大きな力となっています。市場参入企業がこうした変革に適応していく中で、患者の転帰、費用対効果、安全性プロファイルの向上が重視されるようになっています。この進化は、競争上の差別化と利害関係者間の協調的イニシアチブの両方を推進しています。

さらに、デジタルヘルスとデータ分析の進歩は、患者がリアルタイムの情報とエビデンスに基づくガイドラインに基づいて最も適切な治療介入を受けられるよう、個別化された治療軌道を可能にしています。情勢が進化を続ける中、利害関係者は新たな動向を活用し、現在の臨床需要だけでなく、将来の市場課題にも対応しています。この分野の勢いは、成長と革新の有望な時代を下支えし、抗肥満医療における次のブレークスルーの舞台を整えています。

市場力学を牽引する主要セグメンテーション洞察

精緻なセグメンテーションの枠組みが抗肥満治療薬市場の分析を支えており、主要な市場ダイナミクスを詳細に理解することができます。治療タイプに基づくセグメンテーションでは、市場を薬と治療に分解します。一方、薬物療法のカテゴリーには、ブプロピオン-ナルトレキソン、リラグルチド、オルリスタット、フェンテルミン-トピラマート、セマグルチド、ティルゼパチドなどの化合物が含まれ、それぞれが治療成績に独自に貢献しています。一方、治療法のカテゴリーでは、調節可能な胃バンド、内視鏡的スリーブ胃形成術、胃バイパス手術などの手技的介入を掘り下げており、これらは体重管理に対する明確な臨床的アプローチを提供しています。

治療の種類と並行して、薬剤の種類に基づくセグメンテーションでは、市販薬と処方薬を区別します。この区別は、消費者行動と規制の影響を理解する上で重要な役割を果たします。さらに投与経路を調べると、カプセルや錠剤を特徴とする経口投与と、静脈内投与と皮下投与の両方を含む非経口投与の2つの異なるカテゴリーが明らかになります。それぞれの投与経路は、患者のコンプライアンスや治療効果に影響を与えるため、臨床的に考慮すべき点が異なります。

さらに、液剤、半固形剤、固形剤を区別する剤形別の市場セグメンテーションは、製品の安定性とデリバリーメカニズムに関する洞察を提供します。エンドユーザー別セグメンテーションでは、外来手術センター、病院、専門クリニックに市場を分類し、これらの治療が実施される環境の多様性を強調しています。最後に、病院や診療所の薬局、オンライン薬局、小売薬局の役割など、流通チャネルに基づく評価により、市場競争力を高めるアクセスや商業戦略に光を当てています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 運動不足による座りがちな生活習慣の増加
    • 肥満および関連疾患の発生率の増加
    • 新薬の有効性と安全性のプロファイルの向上
  • 抑制要因
    • 抗肥満治療薬の副作用に関する懸念
  • 機会
    • 進行中の臨床試験および研究開発活動
    • 研究開発への投資増加により、最先端の抗肥満薬技術の進歩が促進される
  • 課題
    • 肥満治療に関する一貫した世界的政策の欠如
• 市場セグメンテーション分析
  • 治療の種類：効果が高いため、抗肥満治療薬薬剤が好まれる傾向が高まっている
  • エンドユーザー：病院における抗肥満治療薬の活用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 抗肥満治療薬市場治療の種類別

• 医薬品
  • ブプロピオン-ナルトレキソン
  • リラグルチド
  • オルリスタット
  • フェンテルミン-トピラマート
  • セマグルチド
  • チルゼパタイド
• 治療
  • 調節性胃バンディング
  • 内視鏡的スリーブ胃形成術
  • 胃バイパス手術

第7章 抗肥満治療薬市場薬剤の種類別

• 市販薬
• 処方薬

第8章 抗肥満治療薬市場：投与経路別

• 経口投与
  • カプセル
  • タブレット
• 非経口投与
  • 静脈内
  • 皮下

第9章 抗肥満治療薬市場薬剤処方別

• 液体剤形
• 半固形剤形
• 固形剤形

第10章 抗肥満治療薬市場：エンドユーザー別

• 外来手術センター
• 病院
• 専門クリニック

第11章 抗肥満治療薬市場：流通チャネル別

• 病院・クリニック薬局
• オンライン薬局
• 小売薬局

第12章 南北アメリカの抗肥満治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の抗肥満治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの抗肥満治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Alizyme PLC
• Amgen Inc.
• Arena Pharmaceuticals Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Currax Pharmaceuticals LLC
• Eisai Co. Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• FlaxoSithKline plc.
• GlaxoSmithKline PLC
• Johnson & Johnson Services Inc.
• Merck & Co. Inc.
• Nalpropion Pharmaceuticals Inc.
• Norgine B.V.
• Novartis AG
• Novo Nordisk A/S
• Orexigen Therapeutics Inc.
• Pfizer Inc.
• Rhythm Pharmaceuticals, Inc.
• Sanofi S.A.
• SHIONOGI & Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Vivus Inc.
• Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET MULTI-CURRENCY
• FIGURE 2. ANTI-OBESITY THERAPEUTICS MARKET MULTI-LANGUAGE
• FIGURE 3. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 4. ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTI-OBESITY THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 78. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 79. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 84. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 130. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 131. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 132. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 136. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 140. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 141. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 146. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. INDIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 208. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 228. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 249. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 259. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 269. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 279. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 289. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 290. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 291. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 298. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 299. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 300. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 301. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 308. ISRAEL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 309. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 310. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 311. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 312. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 313. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 314. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 315. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 316. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-20

The Anti-Obesity Therapeutics Market was valued at USD 10.79 billion in 2024 and is projected to grow to USD 11.69 billion in 2025, with a CAGR of 8.59%, reaching USD 17.70 billion by 2030.

The anti-obesity therapeutics sector has undergone remarkable evolution, placing new emphasis on innovative treatments and comprehensive healthcare strategies. Recent advancements have elevated the importance of effective treatment options and procedures in addressing a condition that affects millions globally. As obesity continues to be a leading public health concern, significant investment in research and development for therapeutic interventions has driven a dynamic market environment.

This analysis provides a holistic perspective on the therapeutic landscape, weaving together clinical innovations, patient-centric approaches, and market trends. Recent improvements in drug formulations and surgical interventions reflect the broadening scope of anti-obesity solutions. With governments and private stakeholders prioritizing wellness and preventative care, the market is moving toward targeted and personalized regimens. Stakeholders, including healthcare professionals, investors, and policy makers, are increasingly seeking data-driven insights that offer a clear view of both current practices and future opportunities. The following sections offer an in-depth exploration of transformative shifts in the therapeutic sphere, detailed segmentation insights, regional market dynamics, and strategic perspectives from leading companies operating in this important space.

This report serves as both a guide and a call to embrace the converging trends that are redefining patient care. The ongoing commitment to scientific advancement, in conjunction with pragmatic regulatory adjustments and consumer demand, sets the stage for significant disruption in the anti-obesity treatment market.

Transformative Shifts in the Therapeutics Landscape

In recent years, transformative shifts have redefined the anti-obesity therapeutics landscape. The convergence of technological innovation, deeper clinical insights, and evolving patient needs has spurred a fundamental transformation in therapeutic approaches. Advancements in drug development and precision medicine have paved the way for more efficacious and tailored treatment modalities. The market is witnessing the synthesis of traditional pharmacotherapy with innovative surgical interventions, allowing for integrated treatment plans that address complex patient profiles.

Shifts in regulatory frameworks and increased investments in medical research have further accelerated these changes. New clinical trials, robust data on long-term efficacy, and strategic partnerships among pharmaceutical companies are instrumental in forging novel pathways for treatment. As market participants adapt to these transformative changes, there is a heightened emphasis on patient outcomes, cost-effectiveness, and improved safety profiles. This evolution is driving both competitive differentiation and collaborative initiatives among stakeholders.

Moreover, advancements in digital health and data analytics are enabling personalized treatment trajectories, ensuring that patients receive the most appropriate therapeutic intervention based on real-time information and evidence-based guidelines. As the landscape continues to evolve, stakeholders are leveraging emerging trends to meet not only current clinical demands but also future market challenges. The sector's forward momentum underpins a promising era of growth and innovation, setting the stage for the next breakthrough in anti-obesity care.

Key Segmentation Insights Driving Market Dynamics

An elaborate segmentation framework underpins the analysis of the anti-obesity therapeutics market, which provides a granular understanding of key market dynamics. The segmentation based on treatment type dissects the market into medications and treatments. On one hand, the medications category incorporates a spectrum of compounds including Bupropion-Naltrexone, Liraglutide, Orlistat, Phentermine-Topiramate, Semaglutide, and Tilzepatide; each contributing uniquely to therapeutic outcomes. On the other hand, the treatments category delves into procedural interventions such as Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery, which offer distinct clinical approaches to weight management.

Parallel to treatment types, segmentation based on drug type distinguishes between over-the-counter and prescription drugs. This differentiation plays a crucial role in understanding consumer behavior and regulatory impacts. Further exploration into the route of administration reveals two distinct categories: the oral route, characterized by capsules and tablets, and parenteral administration, which encompasses both intravenous and subcutaneous methods. Each route embodies different clinical considerations, impacting patient compliance and therapeutic effect.

Additionally, market segmentation by drug formulation, which differentiates among liquid, semi-solid, and solid dosage forms, provides insights into product stability and delivery mechanisms. End-user segmentation categorizes the market among ambulatory surgical centers, hospitals, and specialty clinics, highlighting the diverse environments where these treatments are administered. Finally, an evaluation based on distribution channels-including the roles of hospitals and clinics pharmacies, online pharmacies, and retail pharmacies-sheds light on accessibility and commercial strategies that drive market competitiveness.

Based on Treatment Type, market is studied across Medications and Treatments. The Medications is further studied across Bupropion-Naltrexone, Liraglutide, Orlistat, Phentermine-Topiramate, Semaglutide, and Tilzepatide. The Treatments is further studied across Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery.

Based on Drug Type, market is studied across Over-The-Counter Drugs and Prescription Drugs.

Based on Route Of Administration, market is studied across Oral Administration and Parenteral Administration. The Oral Administration is further studied across Capsules and Tablets. The Parenteral Administration is further studied across Intravenous and Subcutaneous.

Based on Drug Formulation, market is studied across Liquid Dosage Forms, Semi-Solid Dosage Forms, and Solid Dosage Forms.

Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.

Based on Distribution Channel, market is studied across Hospitals & Clinics Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Market Insights Shaping Future Strategies

Geographic analysis of the anti-obesity therapeutics market reveals varied trends and challenges across key regions. In the Americas, robust healthcare infrastructures coupled with high patient awareness are fueling demand for both pharmacological and surgical weight management solutions. The region's dynamic regulatory environment encourages innovation and shortens development timelines, thereby accelerating product launches and market penetration. Meanwhile, in Europe, the Middle East and Africa, there is an increasing inclination towards integrating public health initiatives with privately funded research, fostering an environment of balanced growth and improved patient care. Regulatory reforms and cross-border collaborations in these areas are further enhancing market forecasts.

In the Asia-Pacific region, a rapidly expanding middle-class coupled with growing obesity rates is creating new market opportunities for both traditional therapeutics and novel intervention strategies. Economic improvements and changes in lifestyle have heightened demand for accessible, effective treatment options, resulting in an evolving landscape that is both competitive and innovative. The interplay of cultural nuances, healthcare policies, and distribution channel efficiencies has driven region-specific strategies, prompting market players to tailor their products and services to meet local needs effectively.

These regional insights provide strategic guidance for firms planning global expansion, enabling them to align their offerings with the unique healthcare dynamics and market demands of each target area.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies and Their Strategic Movements

The competitive landscape in the anti-obesity therapeutics market is characterized by the presence of several influential players who are setting the pace for innovation and market growth. Leading companies such as Alizyme PLC, Amgen Inc., and Arena Pharmaceuticals Inc. are actively leveraging research breakthroughs to enhance product pipelines and expand their portfolio of therapeutics. These firms work in collaboration with other prominent industry names like Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, and Currax Pharmaceuticals LLC to drive forward advanced treatment protocols.

Other key players, including Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and FlaxoSithKline plc., continue to invest significantly in clinical trials aimed at validating the efficacy and safety of novel therapeutics. Strategic moves by companies such as GlaxoSmithKline PLC, Johnson & Johnson Services Inc., and Merck & Co. Inc. have underlined the market's trend toward increased precision and patient-centric care. Meanwhile, firms like Nalpropion Pharmaceuticals Inc., Norgine B.V., Novartis AG, and Novo Nordisk A/S have identified niche areas within the market to capture unmet needs, further catalyzing competitive dynamics.

Orexigen Therapeutics Inc., Pfizer Inc., Rhythm Pharmaceuticals, Inc., Sanofi S.A., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, Vivus Inc., and Zydus Lifesciences Limited have all executed strategic initiatives that extend beyond traditional drug development to encompass innovative product delivery methodologies and integrated service platforms. The cumulative effect of these strategic movements underscores a market in which both collaborative endeavors and competitive differentiation coexist, providing a fertile environment for sustainable growth.

The report delves into recent significant developments in the Anti-Obesity Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alizyme PLC, Amgen Inc., Arena Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, FlaxoSithKline plc., GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Merck & Co. Inc., Nalpropion Pharmaceuticals Inc., Norgine B.V., Novartis AG, Novo Nordisk A/S, Orexigen Therapeutics Inc., Pfizer Inc., Rhythm Pharmaceuticals, Inc., Sanofi S.A., SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, Vivus Inc., and Zydus Lifesciences Limited. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to embrace several key strategies to optimize their positioning in the anti-obesity therapeutics market. First, it is essential to invest in robust research and development programs that not only focus on improving existing products but also explore new therapeutic modalities. Emphasizing innovation through clinical trials and multi-disciplinary collaborations can lead to breakthroughs that significantly differentiate market offerings.

Second, aligning product portfolios with evolving regulatory standards and patient preferences will be crucial. Organizations should fine-tune their segmentation strategies to cater to diverse treatment options, drug types, and routes of administration. This targeted focus will enhance market penetration by addressing specific needs across both over-the-counter and prescription segments and by optimizing product formulations.

Third, establishing strategic partnerships with healthcare providers and distribution channels, such as hospitals, specialty clinics, and online pharmacies, can greatly expand market access and improve patient engagement. It is also advisable to leverage digital technologies and data analytics to streamline operations and tailor treatment approaches based on real-time insights.

Finally, fostering a customer-centric approach that emphasizes outcomes and cost-effectiveness is imperative. By continuously monitoring market trends and investing in proactive marketing initiatives, industry leaders can bolster their competitive edge and secure long-term growth in an increasingly dynamic healthcare environment.

Concluding Perspectives on Market Opportunities

In conclusion, the anti-obesity therapeutics market is characterized by its rapid evolution and the emergence of a wide array of advanced therapies. The integration of novel drug formulations, dynamic treatment procedures, and a robust focus on targeted patient outcomes underpins the strategic opportunities that lie ahead. Market players have shown a keen understanding of the multifaceted segmentation aspects-ranging from treatment types to drug formulations and distribution channels-demonstrating an ongoing commitment to meeting the diverse needs of patients across different settings.

The analysis underscores the importance of aligning product development with emerging trends, regulatory reforms, and evolving patient behaviors. Regional market disparities further emphasize the need for customized strategies that cater to local market demands while maintaining a global perspective. The collaborative efforts among leading companies, combined with strategic investments in innovation, have set the stage for a new era of growth and value creation in the therapeutics space.

Moving forward, a sustained focus on research, technology adoption, and strategic partnerships will be vital. The conclusions drawn in this comprehensive assessment offer actionable insights that industry stakeholders can leverage to navigate the complexities of the anti-obesity therapeutics market while capitalizing on the opportunities that drive enhanced patient outcomes and long-term commercial success.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising adoption of sedentary lifestyle due to lack of exercise
    • 5.1.1.2. Increasing incidences of obesity and related disorder
    • 5.1.1.3. Enhanced efficacy and safety profiles of newer drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns regarding side effects of anti-obesity therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing clinical trials and research & development activities
    • 5.1.3.2. Increasing investment in R&D propels advancements in cutting-edge anti-obesity drug technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of consistent global policies on obesity treatment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Increasing preference for anti-obesity therapeutics medication due to its higher efficacy
  • 5.2.2. End-User: Expanding utilization of anti-obesity therapeutics in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Obesity Therapeutics Market, by Treatment Type

• 6.1. Introduction
• 6.2. Medications
  • 6.2.1. Bupropion-Naltrexone
  • 6.2.2. Liraglutide
  • 6.2.3. Orlistat
  • 6.2.4. Phentermine-Topiramate
  • 6.2.5. Semaglutide
  • 6.2.6. Tilzepatide
• 6.3. Treatments
  • 6.3.1. Adjustable Gastric Banding
  • 6.3.2. Endoscopic Sleeve Gastroplasty
  • 6.3.3. Gastric Bypass Surgery

7. Anti-Obesity Therapeutics Market, by Drug Type

• 7.1. Introduction
• 7.2. Over-The-Counter Drugs
• 7.3. Prescription Drugs

8. Anti-Obesity Therapeutics Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Oral Administration
  • 8.2.1. Capsules
  • 8.2.2. Tablets
• 8.3. Parenteral Administration
  • 8.3.1. Intravenous
  • 8.3.2. Subcutaneous

9. Anti-Obesity Therapeutics Market, by Drug Formulation

• 9.1. Introduction
• 9.2. Liquid Dosage Forms
• 9.3. Semi-Solid Dosage Forms
• 9.4. Solid Dosage Forms

10. Anti-Obesity Therapeutics Market, by End-User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Anti-Obesity Therapeutics Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Hospitals & Clinics Pharmacies
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies

12. Americas Anti-Obesity Therapeutics Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Anti-Obesity Therapeutics Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Anti-Obesity Therapeutics Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Eli Lilly enhances Zepbound accessibility with affordable single-dose vials to address obesity care inequities
  • 15.3.2. Rani Therapeutics and ProGen join forces to co-develop oral obesity treatment
  • 15.3.3. Click Therapeutics boosts obesity and diabetes pipeline with Better Therapeutics Acquisition
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alizyme PLC
• 2. Amgen Inc.
• 3. Arena Pharmaceuticals Inc.
• 4. Boehringer Ingelheim International GmbH
• 5. Bristol-Myers Squibb Company
• 6. Currax Pharmaceuticals LLC
• 7. Eisai Co. Ltd.
• 8. Eli Lilly and Company
• 9. F. Hoffmann-La Roche Ltd
• 10. FlaxoSithKline plc.
• 11. GlaxoSmithKline PLC
• 12. Johnson & Johnson Services Inc.
• 13. Merck & Co. Inc.
• 14. Nalpropion Pharmaceuticals Inc.
• 15. Norgine B.V.
• 16. Novartis AG
• 17. Novo Nordisk A/S
• 18. Orexigen Therapeutics Inc.
• 19. Pfizer Inc.
• 20. Rhythm Pharmaceuticals, Inc.
• 21. Sanofi S.A.
• 22. SHIONOGI & Co., Ltd.
• 23. Takeda Pharmaceutical Company Limited
• 24. Vivus Inc.
• 25. Zydus Lifesciences Limited